NEW YORK, May 29, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. is investigating potential claims against Ra Medical Systems, Inc. (NYSE: RMED) on behalf of Ra Medical stockholders. Our investigation concerns whether Ra Medical has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
In September 2018, Ra Medical completed its initial public offering (“IPO”), issuing approximately 4.5 million shares of common stock priced at $17.00 per share. On March 14, 2019, the company revealed that its fourth quarter 2018 financial results had been negatively impacted by issues related to the hiring and training of qualified sales personnel and certain production limitations. Since the IPO, Ra Medical stock has declined. As of market close on May 28, 2019, the stock price was $3.60.
If you purchased or otherwise acquired Ra Medical shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning our investigation into Ra Medical please go to https://bespc.com/rmed/. For additional information about Bragar Eagel & Squire, P.C. please go to www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Contacts
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com